Literature DB >> 30676239

Doxorubicin conjugated with nanodiamonds and in free form commit glioblastoma cells to heterodromous fates.

Zhuo Chen1,2, Chao Wang1,2, Tong-Fei Li1,2, Ke Li3, Yuan Yue1,2, Xin Liu1,2, Hua-Zhen Xu1,2, Yu Wen1,2, Quan Zhang1,2, Min Han4, Naoki Komatsu5, Yong-Hong Xu6, Li Zhao7, Xiao Chen1,2.   

Abstract

AIM: To mechanistically compare the effects of doxorubicin (DOX) and DOX conjugated with nanodiamonds (Nano-DOX) on human glioblastoma cells (GC). MATERIALS &
METHODS: GC viablity, proliferation and activation of apoptosis and autophagy was assayed in response to DOX and Nano-DOX. Expression and release of HMGB1 were measured and its role in apoptosis and autophagy probed in response to DOX and Nano-DOX.  
Results: DOX induced apoptosis in GC while Nano-DOX induced autophagy. Inhibition of autophagy in Nano-DOX-treated GC promoted apoptosis. DOX suppressed the emission of HMGB1 while Nano-DOX stimulated HMGB1 emission which was attenuated when autophagy was repressed. Blocking of HMGB1 emission mitigated autophagy and enhanced apoptosis in Nano-DOX-treated GC. Exogenously administered HMGB1 promoted autophagy and protected against apoptosis in both Nano-DOX-treated GC and DOX-treated GC.
CONCLUSIONS: Nano-DOX is a potent autophagy activator as opposed to DOX as an apoptosis inducer. Nano-DOX initiates a mutual reinforcement loop between autophagy and HMGB1 in GC and thereby protects GC against apoptosis.

Entities:  

Keywords:  HMGB1; apoptosis; autophagy; doxorubicin; glioblastoma cells; nanodiamonds

Mesh:

Substances:

Year:  2019        PMID: 30676239     DOI: 10.2217/nnm-2018-0330

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  6 in total

Review 1.  Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer.

Authors:  Aleksandra Benko; David Medina-Cruz; Ada Vernet-Crua; Catherine P O'Connell; Małgorzata Świętek; Hamed Barabadi; Muthupandian Saravanan; Thomas J Webster
Journal:  Cancer Drug Resist       Date:  2021-06-19

Review 2.  Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy.

Authors:  Javad Sharifi-Rad; Cristina Quispe; Jayanta Kumar Patra; Yengkhom Disco Singh; Manasa Kumar Panda; Gitishree Das; Charles Oluwaseun Adetunji; Olugbenga Samuel Michael; Oksana Sytar; Letizia Polito; Jelena Živković; Natália Cruz-Martins; Marta Klimek-Szczykutowicz; Halina Ekiert; Muhammad Iqbal Choudhary; Seyed Abdulmajid Ayatollahi; Bekzat Tynybekov; Farzad Kobarfard; Ana Covilca Muntean; Ioana Grozea; Sevgi Durna Daştan; Monica Butnariu; Agnieszka Szopa; Daniela Calina
Journal:  Oxid Med Cell Longev       Date:  2021-10-18       Impact factor: 6.543

3.  Doxorubicin and CpG loaded liposomal spherical nucleic acid for enhanced Cancer treatment.

Authors:  Bo Deng; Bing Ma; Yingying Ma; Pei Cao; Xigang Leng; Pengyu Huang; Yuanyuan Zhao; Tianjiao Ji; Xueguang Lu; Lanxia Liu
Journal:  J Nanobiotechnology       Date:  2022-03-18       Impact factor: 10.435

Review 4.  Modification of carbon-based nanomaterials by polyglycerol: recent advances and applications.

Authors:  Zeinab Rafiee; Sakineh Omidi
Journal:  RSC Adv       Date:  2021-12-20       Impact factor: 3.361

5.  INPP4B inhibits glioma cell proliferation and immune escape via inhibition of the PI3K/AKT signaling pathway.

Authors:  Xiaoming Sun; Yani Chen; Xiaoyang Tao; Wenzi Zhang; Xinyu Wang; Xianhui Wang; Zhihua Ruan; Zhuo Chen
Journal:  Front Oncol       Date:  2022-09-06       Impact factor: 5.738

6.  Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.

Authors:  Shen-Jun Yuan; Yong-Hong Xu; Chao Wang; Hui-Chao An; Hua-Zhen Xu; Ke Li; Naoki Komatsu; Li Zhao; Xiao Chen
Journal:  J Nanobiotechnology       Date:  2019-10-17       Impact factor: 10.435

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.